公开(公告)号：WO2013055385A3

公开(公告)日：2013-07-04

申请号：PCT/US2012000461

申请日：2012-10-03

Applicant: ZAFGEN CORP ,  HUGHES THOMAS E ,  VATH JAMES E

Inventor： HUGHES THOMAS E ,  VATH JAMES E

IPC: A61K31/336 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/00 ,  A61P3/04 ,  A61P9/00 ,  A61P19/00 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/24 ,  A61P25/28 ,  A61P39/00 ,  A61P39/06

CPC classification number: A61K31/336 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/335 ,  A61K31/7088 ,  A61K31/713 ,  C07D303/08 ,  C07D303/12 ,  C07D303/18

Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.

Abstract translation: 本发明一般涉及治疗患有氧化性窘迫障碍和/或年龄相关疾病和/或处于危险中的患者的方法。 本公开还通常涉及治疗记忆障碍或增强有此需要的患者的认知功能的方法。 这样的方法可以包括施用治疗有效量的MetAP2抑制剂。

公开(公告)号：WO2012075020A1

公开(公告)日：2012-06-07

申请号：PCT/US2011/062413

申请日：2011-11-29

Applicant: ZAFGEN CORPORATION ,  HUGHES, Thomas, E.

Inventor： HUGHES, Thomas, E.

IPC: A61K31/336 ,  A61P3/04

CPC classification number: A61K31/336 ,  A61K9/0019

Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.

Abstract translation: 本发明一般涉及治疗超重或肥胖受试者的方法，并且使用例如MetAP-2抑制剂的非日常给药来治疗超重或肥胖相关病症。

公开(公告)号：WO2009143013A3

公开(公告)日：2009-11-26

申请号：PCT/US2009/044125

申请日：2009-05-15

Applicant: FENNER U.S. INC. ,  WARD, Christopher ,  HUGHES, Thomas, E. ,  NEAL, Matthew, B.

Inventor： WARD, Christopher ,  HUGHES, Thomas, E. ,  NEAL, Matthew, B.

IPC: F16H55/52 ,  F16H55/36 ,  F16H55/00

Abstract: A pulley assembly (30) operable in connection with a tensioner assembly (20) is provided for tensioning a belt. The pulley assembly (30) includes one or more elements for sealing the pulley to protect the pulley assembly in harsh environments. For instance, the pulley assembly may include one or more shields (50,70) for protecting the pulley from contaminants entering the interior of the pulley assembly that can lead to premature failure.

公开(公告)号：WO1994024222A1

公开(公告)日：1994-10-27

申请号：PCT/US1993003376

申请日：1993-04-09

Applicant: HUGHES, Thomas, E. ,  KOTTLER, Daniel, N.

IPC: C09K03/00

CPC classification number: C08L5/12 ,  A61K6/10

Abstract: A hemostatic hydrocolloid gel dental impression material formulated from an agar hydrocolloid modified by the inclusion of potassium sulfate in the amount of between about 4-12 %. The potassium sulfate acts as a hemostatic additive, to cause constriction of the blood vessels and terminate bleeding into the dental impression composition.

Abstract translation: 由通过包含约4-12％的硫酸钾改性的琼脂水胶体配制的止血水胶体凝胶牙印模材料。 硫酸钾充当止血添加剂，引起血管收缩，并终止牙齿印模组合物的渗血。

公开(公告)号：WO2007041251A2

公开(公告)日：2007-04-12

申请号：PCT/US2006/037933

申请日：2006-09-29

Applicant: MONTANA STATE UNIVERSITY ,  GEISINGER HEALTH SYSTEM ,  HUGHES, Thomas E. ,  MEALER, Robert G. ,  BERLOT, Catherine H.

Inventor： HUGHES, Thomas E. ,  MEALER, Robert G. ,  BERLOT, Catherine H.

IPC: C12N15/74 ,  G01N33/53

CPC classification number: G01N33/54386 ,  C07K2319/60 ,  C12N15/1055 ,  C12N15/1082 ,  G01N2500/00

Abstract: A method of detecting protein interactions is described wherein reporter protein fragments are genetically fused at internal positions of suspected interacting proteins. When proteins interact, the fluorescent fragments are brought close enough together to form a functional reporter protein providing visible confirmation of interaction.

Abstract translation: 描述了一种检测蛋白质相互作用的方法，其中报道蛋白质片段在可疑的相互作用蛋白质的内部位置基因融合。 当蛋白质相互作用时，荧光片段足够接近以形成功能性报告蛋白，提供可见的相互作用确认。

公开(公告)号：WO2012074968A1

公开(公告)日：2012-06-07

申请号：PCT/US2011/062320

申请日：2011-11-29

Applicant: ZAFGEN CORPORATION ,  HUGHES, Thomas, E.

Inventor： HUGHES, Thomas, E.

IPC: A61K31/336 ,  A61P3/04 ,  A61K31/00 ,  A61K31/7105

CPC classification number: A61K31/336 ,  A61K31/00 ,  A61K31/7105 ,  A61K45/06

Abstract: The invention generally relates in part to methods of reducing hepatobiliary dysfunction and reducing risk of incident hepatobiliary dysfunction, comprising administering a MetAP2 inhibitor to patients in need thereof. The invention also relates in part to methods of effecting weight loss while reducing hepatic injury or risk thereof, comprising administering a MetAP2 inhibitor.

Abstract translation: 本发明一般部分地涉及减少肝胆功能障碍并降低肝胆管功能障碍发生风险的方法，包括对有需要的患者施用MetAP2抑制剂。 本发明还部分地涉及在减少肝损伤或其风险的同时减轻体重减轻的方法，包括施用MetAP2抑制剂。

公开(公告)号：WO2011088055A2

公开(公告)日：2011-07-21

申请号：PCT/US2011/020866

申请日：2011-01-11

Applicant: ZAFGEN CORPORATION ,  HUGHES, Thomas, E.

Inventor： HUGHES, Thomas, E.

IPC: A61K31/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/336 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/455 ,  A61K31/475 ,  A61K31/505 ,  A61K45/06 ,  A61P3/06

CPC classification number: A61K31/336 ,  A61K31/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/455 ,  A61K31/47 ,  A61K31/505 ,  A61K31/7088 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.

Abstract translation: 本发明一般涉及治疗患有心血管或脑血管障碍和/或处于心血管或脑血管障碍风险的患者的方法。 这样的方法可以包括以基本上不调节血管发生的剂量施用MetAP2抑制剂。

公开(公告)号：WO2011088055A3

公开(公告)日：2011-11-03

申请号：PCT/US2011020866

申请日：2011-01-11

Applicant: ZAFGEN CORP ,  HUGHES THOMAS E

Inventor： HUGHES THOMAS E

IPC: A61K31/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/336 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/455 ,  A61K31/47 ,  A61K31/505 ,  A61K31/7088 ,  A61K45/06 ,  A61P3/06

CPC classification number: A61K31/336 ,  A61K31/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/455 ,  A61K31/47 ,  A61K31/505 ,  A61K31/7088 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.

Abstract translation: 本发明一般涉及治疗患有心血管或脑血管障碍和/或处于心血管或脑血管障碍风险的患者的方法。 这样的方法可以包括以基本上不调节血管生成的剂量施用MetAP2抑制剂。

公开(公告)号：WO2011127304A3

公开(公告)日：2011-10-13

申请号：PCT/US2011/031608

申请日：2011-04-07

Applicant: ZAFGEN CORPORATION ,  HUGHES, Thomas, E.

Inventor： HUGHES, Thomas, E.

IPC: A61K31/336

Abstract: The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor. Type 2 diabetes is a growing health problem affecting more than 20 million people. Type 2 diabetes is often associated with obesity or with weight gain, although patients with normal weight can also suffer from this disease.

公开(公告)号：WO2009143013A2

公开(公告)日：2009-11-26

申请号：PCT/US2009044125

申请日：2009-05-15

Applicant: FENNER US INC ,  WARD CHRISTOPHER ,  HUGHES THOMAS E ,  NEAL MATTHEW B

Inventor： WARD CHRISTOPHER ,  HUGHES THOMAS E ,  NEAL MATTHEW B

IPC: F16H55/52 ,  F16H55/00 ,  F16H55/36

CPC classification number: F16H7/20 ,  F16C13/006 ,  F16C2361/63 ,  F16H2007/0865

Abstract: A pulley assembly (30) operable in connection with a tensioner assembly (20) is provided for tensioning a belt. The pulley assembly (30) includes one or more elements for sealing the pulley to protect the pulley assembly in harsh environments. For instance, the pulley assembly may include one or more shields (50,70) for protecting the pulley from contaminants entering the interior of the pulley assembly that can lead to premature failure.

Abstract translation: 提供可与张紧器组件（20）连接操作的滑轮组件（30），用于张紧皮带。 滑轮组件（30）包括用于密封滑轮以在恶劣环境中保护滑轮组件的一个或多个元件。 例如，滑轮组件可以包括一个或多个屏蔽件（50,70），用于保护滑轮免于进入皮带轮组件内部的污染物，从而导致过早的故障。